RNASE3 and dermatomyositis: In addition, the S1P modulators are recently evaluated in various indications such as autoimmune diseases, dermatomyositis, Crohn’s disease, ulcerative colitis, polymyositis, GvHD and transplant rejection [69], which are also indications for ECP suggesting that similar effects are underlying.